Vol 3, No 1 (March 21, 2014): Chinese Clinical Oncology

Overview: biostatistician’s role in oncology clinical trials—strive for sound, efficient and practical studies

The current design of oncology phase I clinical trials: progressing from algorithms to statistical models

Adaptive randomized phase II design for biomarker threshold selection and independent evaluation

Reducing late effects of radiotherapy in average risk medulloblastoma

EGFR-targeting therapy as an evolving concept: learning from nimotuzumab clinical development

Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2013;(suppl; abstr 3)

Commentary on “aTTom”: long-term effects of continuing adjuvant Tamoxifen to 10 years

Comments on “Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial”

Prof. Peter Yu: opportunities and challenges in big data era

Prof. Shukui Qin: strategy on liver cancer treatment for Asian population

Prof. Jean Armand: personalized medicine in France and the niche in future international cooperation